Romania occupies the last position in the EU innovation ranking — a fact that Business Review raised to ask what residual benefits still accrue to local companies that keep investing in research and development.

For R&D managers working inside Romania, the ranking does double duty. On one level, it serves as a verdict on national innovation policy. On another, it functions as a backdrop against which the budget defence for any in-house research programme gets written.

The Business Review framing matters because it shifts the question from the country level to the firm level. National rankings typically trigger debate about public funding, university capacity, and ministry budgets — concerns that lie mostly outside the scope of a corporate R&D director.

What does fall inside that scope is whether the firm's own research investment moves the needle on anything that matters: tax treatment, grant eligibility, talent attraction, or consortium positioning.

What the ranking does and does not measure

EU innovation rankings combine R&D intensity, patent activity, researcher density, and signals of public–private collaboration. A country in the bottom tier scores low on the input side — underfunding of public research, limited industrial R&D spend — more than on the output side.

For a private R&D unit operating inside such a country, the score reflects the surrounding ecosystem rather than the unit's own productivity.

A software team in Romania building tooling for a Western European parent will register in the country's totals only as a cost line, not as an innovation outcome. The ranking says nothing specific about whether that team's work belongs in the firm's portfolio.

What stays on the table for R&D-active firms

The Business Review headline rests on a premise: that there are benefits to being an R&D-active company in Romania even when the country sits at the bottom of the EU innovation ranking. The piece frames that premise as a question rather than answering it directly, which leaves managers to work through the trade-offs themselves.

For subsidiaries of multinational groups, the trade-off tilts toward cost. Research labour, lab overhead, and operating expenses in Romania remain materially below Western European equivalents, and that cost gap functions as a structural advantage independent of any innovation score.

For domestic firms, the trade-off runs the other way. They absorb the full brunt of a thin local research base — fewer specialised suppliers, fewer academic partners, fewer consortium candidates — and rely more heavily on incentive programmes and grant pipelines to support work that a richer ecosystem would subsidise through collaboration.

The question R&D directors can answer themselves

What the Business Review piece makes clear is that no single answer applies. A multinational R&D centre in Bucharest and a domestic SME running its first funded research project face different incentive landscapes, different cost structures, and different risks. The macro ranking affects both, but through different channels.

For any Romania-based R&D budget built this year, the operative question is not whether the country ranks last in the EU, but which of the channels the ranking affects — grant pipelines, talent markets, consortium positioning, cost — matters most for the specific work being funded.

Directors who work that decomposition themselves will end up with budgets that survive the next reassessment, regardless of how the next EU innovation scoreboard reads.